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EFFICACY OF LOSARTAN AND GROWTH HORMONE  
 
COMBINATORIAL THERAPY IN DyW MICE  
YOUNGHWA RHEE 
ABSTRACT 
Merosin-deficient CMD type 1A (MDC1A) is the second most common form of 
congenital muscular dystrophy (CMD) that presents at or near birth. MDC1A is caused 
by a mutation in the LAMA2 gene which encodes a protein called laminin-2. The 
clinical manifestations of MDC1A include profound muscle weakness, muscle hypotonia, 
loss of independent ambulation, and respiratory failure. There is still no cure or effective 
treatment available for MDC1A patients. In this study we use the Lama2dyW (DyW) 
mouse model which shares analogous phenotypes with the MDC1A disease in humans.  
To this point, therapy development has mainly utilized single-mode therapy. 
While effective in attenuating some aspects of pathology, no single treatment has been 
able to completely ameliorate the multi-faceted pathology of laminin-2 deficiency. 
Therefore this study utilizes a combinatorial treatment strategy with Losartan and Growth 
Hormone to target multiple pathologies simultaneously. 
 Losartan, an angiotensin II type 1 (AT1) receptor antagonist, is commonly used 
in hypertensive patients for its abilities to induce vasodilation. In the context of 
dystrophy, blocking AT1 receptor with losartan inhibits AT1-mediated TGF- signaling 
leading to decreased fibrosis, normalized muscle architecture, and improved muscle 
function and regeneration. Losartan does not, however, induce weight gain in models of 
muscular dystrophy. Growth hormone (GH) is well known to stimulate postnatal skeletal 
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muscle growth as well as overall body weight mainly through Insulin-like Growth Factor 
1 (IGF-1). IGF-1 induces muscle growth via Akt-mediated mTOR activation leading to 
increases in protein synthesis and consequent muscle fiber hypertrophy. Thus we 
hypothesize that the combination of Losartan and GH would alleviates chronic 
inflammation and fibrosis as well as induce weight/muscle gain in DyW mice.  
Dual treatment led to significant gains in total body weight as well as muscle function. In 
addition to the improvements of weights and activities, dual-treated mice showed a more 
normalized distribution of fiber size without increased total fiber number suggesting that 
dual treatment led to muscle hypertrophy not seen in untreated or Losartan-treated DyW 
mice. Myogenesis associated genes, and specifically late markers of myogenic 
differentiation were also significantly upregulated in dual-treated mice indicating a more 
complete and robust myogenic repair compared to untreated and Losartan-treated DyW 
mice, respectively. Dual treatment also led to increased expression of IGF-1 and IGF-1R 
as well as the glucose transporter glut4 suggesting that this strategy also affects insulin 
signaling. This study suggests that a combinatorial anti-fibrotic and pro-myogenic 
therapy achieves a more comprehensive amelioration of downstream pathologies greater 
than single-mode therapies and may be a more suitable treatment regimen for complex 
pathologies such as MDC1A. 
 
  
  vii 
TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS ................................................................................................. iv 
ABSTRACT ........................................................................................................................ v 
TABLE OF CONTENTS .................................................................................................. vii 
LIST OF FIGURES……………………………………………………………………… ix 
LIST OF ABBREVIATIONS ............................................................................................. x 
CHAPTER ONE: BACKGROUND AND INTRODUCTION .......................................... 1 
Congenital Muscular Dystrophy ..................................................................................... 1 
Laminin ........................................................................................................................... 2 
Mouse Model .................................................................................................................. 3 
Losartan........................................................................................................................... 4 
Growth Hormone ............................................................................................................ 5 
CHAPTER TWO: METHODS ........................................................................................... 8 
    Animal Breeding and Care.............................................................................................. 8 
    Drug Treatment ............................................................................................................... 8 
    Functional Tests .............................................................................................................. 8 
    Muscle Tissue Collection ................................................................................................ 9 
    Muscle Histology .......................................................................................................... 10 
    Immunohistochemistry ................................................................................................. 10 
  viii 
    Imaging and Morphometric Analysis ........................................................................... 11 
    Gene Expression ........................................................................................................... 11 
    Statistics ........................................................................................................................ 12 
CHAPTER THREE: RESULTS ....................................................................................... 13 
    Body and Muscle Weights ............................................................................................ 13 
    Functional Tests ............................................................................................................ 15 
    Histological Analysis .................................................................................................... 17 
    Myogenesis ................................................................................................................... 19 
    Insulin Signaling ........................................................................................................... 21 
    Fibrotic Area ................................................................................................................. 23 
    Inflammations and Fibrosis........................................................................................... 24 
CHAPTER FOUR: DISCUSSION ................................................................................... 26 
BIBLIOGRAPHY ............................................................................................................. 31 
CURRICULUM VITAE ................................................................................................... 40 
 
  
  ix 
LIST OF FIGURES 
 
1 Total body weight and hind limb muscle weight of age-matched mice 14 
 
2 Two functional tests of mouse (Standups and Retraction) were performed to   
evaluate the exploratory behavior of mice 16 
 
3 Qualitative and quantitative analysis of hematoxylin and eosin (H&E) 18 
 
4 Myogenesis family gene expression 20 
 
5 qRT-PCR showed the gene expression of IGF-1, IGF-1R and GLUT4 on each    
group to determine effect of insulin in mice 22 
 
6 Picro-sirius red staining showed levels of fibrosis 23 
 
7 Levels of macrophages were detected by immunohistochemistry of Mac-1      
antibody staining and by gene expression 25  
  x 
LIST OF ABBREVIATIONS 
 
ACE...................................................................................Angiotensin-Converting Enzyme 
Ang-II ............................................................................................................. Angiotensin II 
AT1 ...................................................................................................... Angiotensin II type 1 
AT2 ...................................................................................................... Angiotensin II type 2 
CMD .................................................................................. Congenital Muscular Dystrophy 
DyW ........................................................................................ Laminin-2-deficient mouse 
ECM ...................................................................................................... Extracellular Matrix 
GH ............................................................................................................. Growth Hormone 
GS ........................................................................... Gastrocnemius/soleus muscle complex 
H&E ................................................................................................. Hematoxylin and Eosin 
IGF-1 ........................................................................................ Insulin-like Growth Factor 1 
MDC1A..................................................................Congenital muscular dystrophy type 1A 
Mef2 .......................................................................................... Myocyte Enhancer Factor 2 
MRFs...................................................................................... Myogenic Regulatory Factors 
QD ................................................................................................. Quadriceps muscle group 
RAS ............................................................................................. Renin-angiotensin System 
TA ............................................................................................................... Tibialis Anterior 
TGF- .................................................................................. Transforming Growth Factor- 
WT ........................................................................................................................ Wild-type 
 
 1 
CHAPTER ONE: BACKGROUND AND INTRODUCTION 
 
Congenital Muscular Dystrophy 
Congenital muscular dystrophy (CMD) is an inherited neuromuscular dystrophy 
that presents at or near birth [1]. There are many CMDs including Merosin-deficient 
CMD type 1A (MDC1A), Collagen VI-deficient CMD, the dystroglycanopathies, 
SEPN1-related CMD, and LMNA-related CMD - all of which share somewhat similar 
characteristics [1]. General CMD symptoms include muscle weakness and hypotonia 
leading to poor motor abilities as well as spinal deformities [1-3]. Affected muscle 
biopsies show irregular muscle architecture, numerous infiltrating inflammatory cells, 
and increased endomysial connective tissue [2].  
The second most common CMD in the United States and most prevalent 
(accounting for 30-50% of diagnosed CMDs) in Europe is Merosin-deficient CMD type 
1A (MDC1A). The prevalence of MDC1A is estimated at 7 in 1,000,000 people [4]. 
MDC1A is an autosomal recessive disease due to a mutation in LAMA2, the gene which 
encodes the 2 chain of Laminin-211 [1, 5, 6]. Similar to other forms of CMD, the 
clinical manifestations of MDC1A include profound muscle weakness, muscle hypotonia, 
respiratory failure, loss of independent ambulation, massive signaling dysregulation, high 
serum creatine kinase concentrations and white matter signal abnormalities (although 
mental retardation is less prevalent) [1, 6, 7]. Despite significant advances in MDC1A 
research, there is still no cure or treatment available for MDC1A patients. Thus, palliative 
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care, such as ventilator support, physical therapy, and mechanical assistive devices 
remain the only options to improve quality of life and increase life expectancy [1].  
 
Laminin 
Laminin is a cross-shaped heterotrimeric protein that consists of one alpha, one 
beta, and one gamma chain. Each subunit has several isoforms including five alpha, three 
beta, and three gamma genetic variants which produce at least 16 distinct isoforms of 
laminin [4, 8]. The Laminin-211 isoform, also known as merosin, is the most abundant 
isoform that makes up the skeletal muscle basement membrane and is also expressed in 
the Schwann cell lamina. Functionally, laminin is an integral protein for providing 
structural scaffolding of muscle cells. Laminin-211 serves as a critical link between 
structural proteins of extracellular matrix (ECM) and the dystrophin-glycoprotein 
complex (DGC), a larger network of protein connecting cells to the ECM [9]. Since many 
proteins are involved and play important roles in the DGC, mutations in virtually any of 
these proteins result in some form of muscular dystrophy.  
The ECM is comprised of an interstitial matrix and basal membrane. Major ECM 
components are protein fibers such as collagen and elastin, proteoglycans, and adhesive 
glycoprotein molecules such as fibronectin and laminin [10]. ECM not only integrates its 
different components, but also maintains normal tissue function, such as muscle 
contraction in the case of skeletal muscles. It also plays a critical role in signal 
transduction necessary for vital functions such as muscle repair and regeneration [11]. 
One of the major ECM muscle proteins is collagen, mostly type IV collagen. It is closely 
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associated with integrin 71 and -dystroglycan [11, 12].  
Integrin 71 and -dystroglycan are the two functional laminin receptors that 
link the ECM to the muscle membrane; therefore, deficiency of Laminin-211 limits the 
connection of functional laminin receptors with the ECM and causes severe signaling 
defects [13]. Patients afflicted with MDC1A show secondary dysregulation of -
dystroglycan and integrin 71, both of which are necessary for proper proliferation and 
repair of muscle cells [6, 8, 14, 15]. Loss of laminin-211 results in severe signaling 
dysregulation and secondary manifestations of inflammation, apoptosis, and fibrosis that 
consequently result in limited or absent regeneration and progressive degeneration of 
skeletal muscles [8, 16, 17].  
 
Mouse model 
There are five different mouse models for MDC1A including Lama2dy, Lama2dy2J, 
Lama2dy3K, Lama2dyW, and Lama2dynmf417 [4]. Lama2dy and Lama2dy2J are spontaneous 
mutations that result in a mild MDC1A phenotype [4]. Lama2dy3K and Lama2dyW have 
targeted mutations in the LAMA2 gene resulting in a more severe phenotype that more 
closely resembles human disease progression [4, 8, 12, 15]. Lama2dy3K mice are 
completely deficient in Lama2, and present an extremely severe phenotype and poor 
survival rate, therefore, it is a very challenging model for MDC1A research. In this study, 
we use the Lama2dyW (DyW) mouse model, which expresses a truncated form of 




Dysregulation of the renin angiotensin system (RAS) has been shown to play a 
role in skeletal muscle regeneration and muscle wasting [18]. Angiotensin II (Ang-II) is 
produced via activation of angiotensinogen by angiotensin-converting enzyme (ACE). 
Ang-II binds to two receptors: angiotensin II type 1 (AT1) receptor and angiotensin II 
type 2 (AT2) receptor. Downstream consequences of overactive Ang-II signaling have 
been associated with skeletal muscle wasting and impaired muscle regeneration due to its 
inhibitory effect on satellite cell activation and proliferation [19, 20]. It is reported that 
binding of Ang-II to its receptor (AT1 receptor) also facilitates phosphorylation of Smad 
proteins, intermediates of Transforming growth factor- (TGF- signaling pathway [5]. 
TGF- is an important cytokine that drives fibrosis by phosphorylating its downstream 
target, Smad family of transcription factors. Phosphorylated Smad2/3 binds to Smad4 and 
translocates to the nucleus to regulate the transcription of fibrotic genes [21]. 
Interestingly in mdx mice (a mouse model for Duchenne muscular dystrophy), Ang-II 
signaling through AT2 has shown to upregulate TGF- signaling, an action that triggers 
muscle fibrosis [19, 22]. Thus, controlling the Ang-II-TGF- axis is a logical approach to 
attenuate fibrotic pathology. 
Losartan, an AT1 receptor antagonist, is an FDA-approved drug for treatment of 
hypertension by lowering blood pressure through vasodilation. Losartan blocks AT1 
receptor and prohibits binding of Ang-II to the receptor, consequently maintaining Ang-II 
in its inactive form [5]. Several studies in different mouse models of muscular dystrophy 
including mdx, Lama2dy2J, and Lama2dyW have shown that Losartan decreases infiltrating 
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macrophages, induces reduction of inflammation and fibrosis, and improves muscle 
architecture [5, 23, 24]. A study using a mouse model with a cardiotoxin (CTX)-induced 
injury shows AT1 receptor blockade suppresses TGF- signaling and enhances muscle 
regeneration and function [19]. In different mouse models of MDC1A, noted reduction in 
fibrosis and improved muscle architecture in response to Losartan is also accompanied by 
downregulation of phosphorylated Smad protein [5, 25-27].  
While Losartan is effective in attenuating chronic inflammation and fibrosis, it 
does not, however, augment muscle or body weight of dystrophic mice [5]. Although in 
sarcopenia mouse models, IGF-1/Akt/mTOR pathway is upregulated in Losartan-treated 
mice and protects against the loss of muscle mass, DyW mice on Losartan treatments 
show limited or no weight gain [28]. Because failure to thrive is a critical co-morbidity 
factor in this disease, we believe that offsetting some of negative effects of Losartan on 
muscle growth by combining Losartan treatment with an anabolic intervention is a 
rational approach that could lead to a better outcome for MDC1A.  
  
Growth Hormone 
Growth hormone (GH) is known to enhance postnatal skeletal muscle growth and 
body weight [29]. GH has been used widely as a supplement for people with growth 
hormone deficiency (GHD) and treating various growth disorders in children [29-31]. 
The anabolic actions of GH improve protein balance and protein oxidation, leading to an 
increase in lean body mass [32]. The anabolic effects of GH are mediated via insulin-like 
growth factor-1 (IGF-1), which is associated with enhanced proliferation, differentiation, 
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and cell survival leading to improved regeneration and muscle hypertrophy [30, 32-36]. 
IGF-1 is produced in the liver as well as in the muscle and is a potent mediator of bone 
and muscle regeneration [37]. GH binds to its receptor and mediates expression of IGF-1, 
which in turn activates the Akt pathway, a major mediator of cell growth, proliferation, 
and regeneration. Akt achieves this through mTOR, a master growth regulator and 
controller of protein synthesis [38, 39]. 
MDC1A is a multifaceted disease with many affected signaling pathways. While 
some therapies have shown promise, no single treatment has been able to completely 
ameliorate all the various pathologies associated with laminin-2 deficiency. Therefore, 
this study was designed to investigate whether combinatorial treatment could tackle 
multiple pathologies to result in a better outcome with DyW mice. 
Our previous studies with IGF-1 overexpression in transgenic DyW mice show 
improved muscle regeneration leading to increased lifespan and muscle function, 
however chronic inflammation and fibrosis is worsened in DyW mice [34]. Since 
Losartan alleviates chronic inflammation and fibrosis, and IGF-1 enhances weight gain, 
we hypothesized that the dual treatment of GH and Losartan can expand the therapeutic 
target of MDC1A by virtue of offsetting negative effects of each other. 
Although there is evidence of muscle growth in IGF-1, this study utilizes GH 
instead of IGF-1 because GH has been utilized in children for many years while 
recombinant IGF therapeutics are still under clinical trials. Furthermore, because GH is 
upstream of IGF-1, there could be more potential roles along with muscle regeneration. 
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CHAPTER TWO: METHODS 
Animal Breeding and Care 
All animals were housed at the Laboratory Animal Care Facility at the Charles 
River Campus (LACF-CRC) at Boston University on a 12:12-hr light-dark cycle. Food 
and water were provided ad libitum. All procedures were performed in accordance to the 
protocol approved by the Institutional Animal Care and Use Committee (IACUC) at 
Boston University. Heterozygous B6.129 Lama2dyW+/- mice, carrying a targeted mutation 
in the Lama2 gene, were kindly provided by Dr. Eva Engvall (Burnham Institute, La 
Jolla, CA, USA).  
 
Drug Treatment  
In this study, DyW animals were randomly assigned to three groups for short-
term study. Lama2dyW-/-, Lama2dyW-/-Losartan, Lama2dyW-/-GH and Losartan-treated mice. 
Losartan and Growth Hormone (GH) treatments were started at two weeks post-natal and 
continued until tissue collection at seven weeks of age. Losartan (Cozaar; Merck 
pharmaceuticals), was provided in the drinking water ad libitum at 600mg/L, while  GH 
was administered by intraperitoneal injections at a dose of  0.5mg/Kg/day. 
 
Functional Tests 
Two non-invasive tests were performed weekly on the treated and control mice 
between 3-7 weeks to assess their muscle functions. One of these tests, called Stand-Up 
Test, relies on the normal exploratory behavior of healthy mice. A healthy mouse stands 
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up several times on its hind limbs every minute, with the number of standups being 
proportional to the strength of their muscles. For this test, a mouse was transferred to a 
clean cage and allowed to acclimate for 5 minutes before recording. The number of times 
the animal stood up only on its hind limbs during a 5-minute period was recorded. 
Another test called the Limb Retraction Test also measures the strength of hind limb 
muscles. When mice are suspended in air by holding their tails, they keep their legs 
extended until muscles become fatigued and they are forced to retract their legs. 
Dystrophic mice typically have short retraction time due to their weakened muscle, and 
this retraction time is proportional to the measure of strength of their limb muscles. For 
this test mice were suspended by their tails for up to 10 seconds and the times at which 
they retract their limbs were recorded. These tests were performed three times and the 
numbers were averaged. 
 
Muscle Tissue Collection 
Animals were euthanized with isoflurane (Webster Veterinary, Devens, MA, 
USA) before isolating the tibialis anterior (TA), gastrocnemius-soleus complex (GS), and 
quadriceps (QD). Tissues were weighed and snap-frozen in liquid nitrogen for RNA and 
protein extraction. TA muscles used for histology were embedded in Tissue-Tek OCT 
compound (Sakura Finetek USA, Torrance, CA, USA) and frozen using 2-methylbutane 
(Sigma-Aldrich, St. Louis, MO, USA) that was chilled in liquid nitrogen. Serial 
transverse sections (7m) were prepared using a Leica CM1850 cryostat (Leica 
Microsystems, Buffalo Grove, IL, USA) and stored at -800C for histological analysis.  
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Muscle Histology 
Frozen sections were air-dried at room temperature for 15 minutes and fixed in 
chilled acetone for 5 minutes. Sections were hydrated through decreasing grades of 
alcohol. Mid-belly sections were stained with hematoxylin (Fisher Scientific, Fair Lawn, 
NJ, USA) for 1 minute, followed by development in 1% ammonium hydroxide for 1 
minute. Sections were subsequently stained with Ruben’s Eosin-Phloxine working 
solution (Fisher Scientific) for 2 minutes. After dehydration through increasing grades of 
alcohol and xylene, sections were mounted using Cytoseal mounting medium (Thermo 
Fisher Scientific).  
Picro-Sirius Red (American MasterTech Scientific, Lodi, CA, USA) staining was 
performed according to the manufacturer’s instructions. Briefly the sections were fixed 
with acetone and rehydrated as described above. Once the sections were rehydrated, they 
were stained with Picro-Sirius Red solution for 15 minutes, rinsed twice in 0.5% acetic 
acid, and dehydrated with increasing grades of alcohol and xylene. The sections were 
subsequently mounted in Cytoseal medium.  
 
Immunohistochemistry 
Frozen tissue slides were air-dried at room temperature for 10 minute, fixed in 
chilled acetone for 10 minutes and air-dried for 10 minutes. Sections were washed twice 
for two minutes each with Phosphate Buffer Saline (PBS). Slides were then incubated 
with Mouse on Mouse (M.O.M.) blocking solution (Vector Labs; Burlingame, CA, 
USA), for 60 minutes. For staining with the anti Mac-1 antibody, the sections were 
 11 
incubated with Alexa 488 conjugated anti-CD11b antibody (1:200 dilution; BD 
biosciences, San Jose, CA, USA) for 45 minutes in the dark. Nuclei were stained with 
DAPI (1 g/ml) for 5 minutes. The sections were then washed three times with PBS for 5 
minutes each. Sections were subsequently mounted with PBS: Glycerol (1:2). 
 
Imaging and Morphometric Analysis 
Stained sections were imaged with a Nikon DSFi1 camera head attached to a 
Nikon ECLIPSE 50i light/immunofluorescence microscope system. Morphometric 
analyses (myofiber size, fibrotic area, and cross-sectional area) were performed using 
NIS-Elements Basic Research 3.0 software.  
 
Gene Expression 
RNA from 25mg of snap-frozen hind-limb muscle tissues (TA, GS, and QD) was 
extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. RNA (1 g) was reverse-transcribed with the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Gene 
expression analysis was carried out using Taq-Man gene expression assays (Applied 
Biosystems, Foster City, CA, USA) on the Applied Biosystems 7300 Real-Time PCR 
System. 18s ribosomal subunit RNA served as the endogenous control, and fold change 





Statistical analyses were performed using GraphPad Prism 6 software (GraphPad 
Software, La Jolla, CA, USA) and included two-way analysis of variance (ANOVA) 
followed by Tukey’s multiple comparison analysis as well as unpaired two-tailed t-test. 
Data are presented as mean +/- standard deviation.
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CHAPTER THREE: RESULTS 
 
Body and Muscle Weights 
The body weight of each group was recorded every week to use as an outcome 
measurement and to determine the efficacy of each treatment on DyW mice model. 
Compared to untreated DyW mice, DyW-GH + Losartan-treated mice showed significant 
weight gain from postnatal weeks 4 to 6 (p < 0.05 and p < 0.01 by 2-way ANOVA, n = 6-
7). From week 4 to 7, there was a significant difference in weight between DyW-
Losartan-treated and DyW-GH + Losartan-treated group (p < 0.05 and p < 0.001 by 2-
way ANOVA, n = 6-7). However, there are no significant differences in weights between 
DyW untreated mice and DyW-Losartan-treated mice throughout the study. (Figure 1A). 
Growth rate for all treatment groups are still significantly smaller than age-matched WT 
mice (data not shown). 
We further determined the effects of single and combinatorial therapy on hind 
limb muscles: Tibialis anterior (TA), Gastrocnemius/soleus (GS), Quadriceps (QD). 
Also, there were significant differences in GS and QD muscle weights between untreated 
DyW mice and DyW-GH + Losartan mice (p < 0.01 and p < 0.0001 by 2-way ANOVA 
respectively, n = 4-6). DyW-GH + Losartan-treated mice QD muscle was significantly 











Stand-up and hind limb retraction tests were utilized as an assessment of muscle 
function by the total number of times of hind limb stand ups and total second of hind 
limb extensions with tail suspension. Both DyW-Losartan and DyW-GH + Losartan-
treated mice showed significant increase in standups compared to untreated DyW-mice (p 
< 0.0001 and p < 0.01 by one-way ANOVA respectively, n = 6-8). DyW-GH + Losartan-
treated mice increased muscle strength over untreated mice. (Figure 2A).  
A similar trend was seen for the time in hind limb retractions. Both DyW-
Losartan and DyW-GH + Losartan-treated mice showed significant increases in retraction 
compared to DyW mice (p < 0.001 and p < 0.05 respectively by one-way ANOVA, n = 
6-7). DyW and both treatment groups had significantly lower retraction time compared to 










Histological evaluation of Hematoxylin and eosin (H&E) stained tissue sections 
was utilized for evaluation of tissue architecture as the primary diagnostic technique. 
Notice the disrupted tissue architecture in the DyW – it reveals extremely variable fibers 
with many regenerating fibers (as seen by centrally nucleated fibers). The tissue had 
larger interstitial space that was filled with infiltrating inflammatory cells as well as 
fibrotic extracellular material deposition (Figure 3B). Both DyW-Losartan and DyW-GH 
+ Losartan treatment showed improvement in the tissue health by virtue of reduced 
interstitial space, infiltrating cells and fibrotic materials (Figure 3C and D). 
The total number of fibers and minimum feret constituted morphometric analysis 
of the H&E stained sections. Total number of fiber counts in DyW, Losartan-treated, and 
GH + Losartan-treated group were significantly smaller than WT group (p < 0.0001 by 
one-way ANOVA, n = 4), but there were no significant differences in the fiber numbers 
among DyW, DyW-Losartan, and DyW-GH + Losartan groups (Figure 3E).  
Although all DyW and treated groups shared similar total number of fibers, the Minimum 
Feret, which showed the minimum average diameter size of the single myofiber, was 
different in the two treatment groups compared to the untreated DyW. DyW-Losartan-
treated group showed much smaller myofiber sizes than any other groups. GH + Losartan 
mice showed more normalized distribution of myofiber sizes by shifting to the right 





To determine the extent of myogenesis, we looked at gene expression of 
myogenic regulatory factors (MRFs) and myocyte enhancer factor 2 (Mef2). Interestingly 
the expression of all these factors were significantly higher in the DyW-GH + Losartan-
treated mice compared to DyW-Losartan-treated mice (p < 0.0001 by one-way ANOVA, 
n = 4-7) (Figure 4A-F). Untreated DyW mice had significantly upregulated MyoD, 
Myogenin, and p21 compared to littermate WT (p < 0.01 and p < 0.0001 by one-way 
ANOVA, n = 4-10) (Figure 4B, D, and E). DyW-Losartan single-treated mice had 
significantly downregulated Myf5, MyoD, Myogenin, and p21 compared to untreated 
DyW (p < 0.01, p < 0.0001, p < 0.5 by one-way ANOVA, n = 4-10) (Figure 4A, B, D, 
and E).  Unlike MRFs, mef2c gene expression showed significant downregulation in  
DyW and losartan-treated mice compared to WT (p < 0.0001 by one-way ANOVA, n = 
4-7). However, GH + losartan-treated mice were upregulated in mef2c compared to WT 
(p < 0.01 by one-way ANOVA, n = 4) and compared to DyW and DyW-Losartan-treated 





Since GH plays a role in anabolic metabolism mediated through IGF-1, we looked 
at gene expression of IGF-1 and IGF-1 receptor (IGF-1R) as an assessment of insulin 
signaling pathways. DyW-GH + Losartan-treated mice showed significant upregulation 
in IGF-1 compared to all other groups (p < 0.0001 by one-way ANOVA, n = 5-8) (Figure 
5A). Also, they showed significant upregulation in IGF-1R compared to WT, DyW, and 
DyW-Losartan-treated mice (p < 0.01, p < 0.01, p < 0.0001 respectively by one-way 
ANOVA, n = 5-8) (Figure 5B).  
Glut4 is a glucose transporter that increases glucose uptake in skeletal muscle. 
Glut4 was significantly downregulated in DyW and Losartan-treated mice compared to 
WT and DyW-GH + Losartan-treated mice (p < 0.0001 by one-way ANOVA, n = 6). 
Glut4 expression in GH + Losartan-treated mice was completely rescued back to WT 









To evaluate the extent of fibrosis, we used Picro-Sirius Red staining to stain 
collagen fibers in ECM red. However, DyW showed larger areas of fibrosis that were 
stained in large area of interstitial spaces in between fibers due to a high presence of 
collagen (Figure 6B). DyW-Losartan and DyW-GH + Losartan treatment showed less 





Inflammation and Fibrosis 
Chronic inflammation is detrimental to muscle health. Therefore we evaluated the 
level of infiltrating macrophages by immunostaining Mac-1 antibody and corresponding 
to gene expression of CD11b, a marker for macrophages. Within untreated and treated 
sections, DyW-Losartan had the least infiltrating Mac-1 positive cells and DyW-GH + 
Losartan sections had the most patches of Mac-1 positive cells (Figure 7D). Also, CD11b 
gene expression showed significant upregulation in DyW-GH + Losartan-treated mice 
compared to WT, DyW, and DyW-Losartan-treated mice (p < 0.0001, p < 0.01, and p < 
0.0001 respectively by one-way ANOVA, n = 5-8) (Figure 7E). Both Mac-1 antibody 
staining and CD11b gene expression in DyW-Losartan-treated mice were rescued back to 
WT level and had no significant differences with age-matched WT (by one-way 




CHAPTER FOUR: DISCUSSION 
 
Combinatorial treatment of GH and Losartan results in similar growth rate (as 
shown by parallel slope in the growth curve) comparing to WT, which we do not see in 
untreated DyW or Losartan-treated DyW mice. WT and the dual-treated mice show 
significant growth spurt beginning at week 3 compared to the other two groups, albeit 
total body weight in dual-treated DyW mice is still much smaller than age-matched WT 
mice. In line with increase in total body weight, GH + Losartan combinatorial therapy 
also induces increase in hind limb muscle weight. Our previous work showed that DyW 
mice virtually lacked any postnatal growth due to limited regeneration combined with 
apoptosis [17]. We and other researchers have subsequently shown that treating with 
Losartan alone had no effect on total body and muscle weight throughout development 
although there was a marked improvement on pathology.  Thus our results suggest that 
adding the GH with the Losartan treatment could be beneficial for overall growth on 
DyW mice. Because lack of growth in MDC1A is playing a large role in driving this 
disease, a treatment strategy such as this one could clearly improve disease outcome. 
We next assessed fiber size distribution using quantitative morphometric analyses 
of Hematoxylin and Eosin stained muscle sections. We found that muscle fiber size did 
not increase in hind limb in response to Losartan. In fact, the muscle fiber size 
distribution in Losartan-treated mice is even smaller than average distribution of DyW 
mice. However, despite the large percentage of small myofibers in Losartan-treated mice, 
the muscle architecture as a whole is improved including lesser interstitial spaces and 
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fewer infiltrating mononucleated cells. Other studies have shown similar results in triceps 
and diaphragm muscle in dystrophic mice [5]. While mice in the dual treatment group did 
not increase in total fiber numbers in comparison of untreated and Losartan-treated DyW 
mice, the average myofiber size was larger and reflected a more normalized distribution 
in addition to improved muscle architecture. Taken together, an increase in fiber size 
suggests improved myogenesis/muscle hypertrophy to be a result of GH + Losartan dual 
treatment leading to larger muscles although further experimentation is needed to confirm 
this hypothesis.  
As explained above, improved myogenic program could be responsible for 
increased fiber size that we see in dual treatment. When muscle cells are injured, satellite 
cells begin to proliferate to form myoblasts which migrate and fuse with one another to 
form myotubes [39, 40]. This process is governed by muscle-specific transcription factors 
called muscle regulatory factors (MRFs) [39]. Our results show that there is indeed an 
increase in the expression of several myogenic factors in response to dual-treatment. In 
contrast, many MRFs are significantly downregulated with Losartan treatment. 
Specifically we see upregulation of p21, one of the key regulators of cell cycle 
progression and a well-known as a cyclin-dependent kinase (CDK) inhibitor 1, that is 
required for terminal differentiation of skeletal cell upon withdrawal from cell cycle and 
consequent myoblasts fusion [41, 42]. We also see upregulation of both Mrf4 and 
Myogenin in response to dual treatment. Because both of these transcription factors are 
regarded as differentiation genes, we speculate that they could also play a role in more 
complete myogenesis in response to dual-treatment. Of our particular interest, we find 
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increased expression of mef2c in response to dual-treatment compared to untreated DyW 
or Losartan-treated DyW mice (also WT). MEF2 family includes mef2a-d and plays a 
critical role in morphogenesis and myogenesis of skeletal, cardiac, and smooth muscle 
cells [43, 44]. Each member of the MEF2 family has a different temporal pattern of 
expression; thus, further experimentation of each MEF2 family is required to comprehend 
the full skeletal muscle development [44]. For the purpose of this study, mef2c is 
investigated because it is required for differentiation from non-muscle cells into skeletal 
muscle during late myogenic differentiation [40, 45, 46]. Inactivation of mef2c results in 
early lethality in skeletal and cardiac muscle development [46, 47]. Interestingly, our 
results show that dual-treatment results in significantly high expression of mef2c 
compared to all other groups, whereas untreated DyW and DyW-Losartan-treated mice 
express significantly lower levels. The higher mef2c expression of dual-treated mice 
could explain a more complete or improved myogenesis. Overall, the expression levels of 
MRFs and mef2c in response to dual-treatment suggest a more complete myogenic 
process in response to dual therapy.  
Because IGF-1 pathway is one of the most important regulatory mechanisms for 
coordinating postnatal skeletal muscle growth and muscle hypertrophy [30, 48-51], we 
next looked at some of the genes in these signaling pathways. The upregulation of IGF-1 
and IGF-1R gene expression on dual-therapy suggests that IGF-1 signaling is increased. 
Additionally, the insulin-stimulated glucose transporter, GLUT4, gene expression in 
response to dual-treatment is very similar to WT level whereas it is significantly 
downregulated in untreated DyW and Losartan-treated mice. Increased expression of 
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GLUT4 in dual-treatment could explain to some extent the increased muscle weight and 
myofiber size. In addition, it could be a consequence of upregulation of mef2c in dual-
therapy. Upregulation of mef2c increases oxidative metabolism in skeletal muscle and a 
fiber-type shift towards slow-phenotype that are also known to overexpress GLUT4 [52]. 
However, more extended experimentations of glucose metabolism are needed to support 
these arguments. 
Muscle function was assessed using two functional tests - standups and hind limb 
retraction. Standing up on hind limbs is a common exploratory behavior of healthy mice; 
therefore, this test can be used as a barometer of muscle health. Hind Limb Retraction 
tests show the ability of muscle to generate strength until muscles are fatigued. Both 
standups and hind limb retraction tests of single- and dual-treated mice exhibit 
significantly better activities than untreated DyW mice. These functional phenotype tests 
validate improvement in hind limb muscle function in response to single- and dual-
treatment. However we do not see additional improvement of dual-treatment compared to 
single-treatment. Perhaps due to heavier weight or some degree of inflammation and 
fibrosis of dual-treatment, it does not result in additional functional improvement.  
Chronic inflammation is one of the major pathologies seen in many muscular 
dystrophies, and we investigate whether levels of inflammation and fibrosis are improved 
in response to single- or dual-treatments. Interstitial fibrosis can be critically detrimental 
to muscle function and is common secondary pathology in many dystrophies. We 
assessed the extent of fibrosis Picro-Sirius red, which stains connective tissue, and more 
specifically, collagen red. Both single- and dual-treatment lead to reduction in the 
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amounts of fibrotic areas compared to untreated DyW mice.  
When tissues are damaged or injured, macrophages migrate to the damaged or 
injured area to clear cellular debris for tissue regeneration [53]. Although macrophages 
are required for muscle regeneration, chronic infiltration of these cells leads to 
inflammation and fibrosis. The immunohistostaining with Mac-1 (anti-CD11b) antibody 
and gene expression of CD11b show that macrophage infiltration is attenuated by 
Losartan treatment but intensified by GH + Losartan treatment from both Mac-1 staining 
and CD11b gene expression. Because GHR is expressed on macrophages, GH 
supplement would have impact on macrophages expression; however, the mechanism is 
still unclear [54]. Therefore, the reason for increased number of macrophages in response 
to dual treatment needs further investigation.  
Children with MDC1A suffer from the dysregulation of many cellular 
mechanisms such as progressive inflammation, fibrosis, and regenerative failure leading 
to impaired muscle growth [17, 55]. The Losartan single-mode of therapeutic approach 
emphasizes the need of combinatorial therapy to simultaneously target multiple 
pathologies of MDC1A. In this study, the dual-treatment has shown efficacy in the major 
pathologies in DyW mice; however, it requires more research on protein expression or 
survival in order to understand the effective mechanism of combinatorial therapy. Based 
on these results, dual-therapy warrants further research, necessitating further 
investigations of combination or sequential treatment strategies as this combinatorial 
therapy could be viable therapy option for MDC1A. 
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